Actively Recruiting
Shortwave Intervention for Diabetic Peripheral Neuropathy A Randomized, Single-Blind, Sham-Controlled Trial SIDPN
Led by Chongqing Medical University · Updated on 2026-06-18
202
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of shortwave therapy to treat diabetic peripheral neuropathy in a randomized, single-blind, sham-controlled clinical trial. The study aims to assess the effectiveness and safety of this therapy in improving neurological symptoms in patients aged 18 to 85 years who have diabetic peripheral neuropathy and have not responded to prior treatments like mecobalamin. The primary goal is to measure the remission rate using the Toronto Clinical Scoring System one month after treatment. Participants are randomly assigned to either receive shortwave therapy or a sham treatment that looks and sounds identical but does not emit electromagnetic energy. The therapy involves placing both lower limbs in a device set to 250W power and 27.12 MHz frequency for 20 minutes daily over five consecutive days. The sham group undergoes the same process without actual electromagnetic energy, maintaining blinding by measuring skin temperature before and after treatment without revealing values to participants. During the study, participants are assessed for changes in neurological scores, pain levels, and quality of life within five days and one month after treatment. Safety indicators are also monitored throughout. The main measurement is the remission rate of neuropathy symptoms at four weeks. The trial includes patient global impressions of change and response rates. Participation lasts for the treatment period plus follow-up assessments up to one month after treatment.
CONDITIONS
Brief Title
Shortwave Intervention for Diabetic Peripheral Neuropathy.
Research Team
J
Jinbo Hu, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here